On July 26, Bio-TechnologyAn announcement was issued stating that its wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. (referred to as "Jinyu Baoling"), in conjunction with Beijing Hesheng Gene Technology Co., Ltd., has obtained the clinical trial approval certificate for feline infectious peritonitis mRNA vaccine issued by the Ministry of Agriculture and Rural Affairs (approval number: 2025062), becoming the first company in China to obtain a clinical approval certificate for this type of veterinary nucleic acid vaccine.

It is understood that feline infectious peritonitis is caused by feline infectious peritonitis virus (FIPV), which is a highly contagious disease with a mortality rate of up to 100%. Currently, there is no commercial vaccine in the world. The vaccine approved this time adopts the mRNA technology route, integrating AI algorithms and structural biology during the research and development process .A large number of animal experiments were conducted to screen out core targets for effective protection, with a total R&D investment of approximately RMB 6.2 million.

As a new innovative vaccine, this product has overcome the technical difficulties of antigen design and nucleic acid vaccine industrialization, laying a key foundation for Biopharmaceuticals ' layout in the field of veterinary nucleic acid vaccines. The announcement shows that the clinical trial will be led by Jinyu Baoling and carried out at the approved location and within the validity period.

However, the vaccine development cycle is relatively long, and it needs to complete clinical trials, registration and application, and can only be sold after obtaining a new veterinary drug certificate and approval number from the Ministry of Agriculture and Rural Affairs. There are uncertainties in the development progress and industrialization effect. Biostime said it will closely follow the progress and fulfill its information disclosure obligations in a timely manner.

Source：https://finance.eastmoney.com/a/202507263468258073.html